Status and phase
Conditions
Treatments
About
This is a phase 3 Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
504 participants in 2 patient groups
Loading...
Central trial contact
Dr. Harish Shandilya
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal